購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
huPBMC-NKG Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huPBMC-NKG Mouse
製品名
huPBMC-NKG Mouse
製品ID
C001329
系統名
huPBMC-NOD.Cg-PrkdcscidIl2rgem1cya/Cya
背景情報
NKG
状況
このマウス系統を論文で使用する場合は、「huPBMC-NKG Mouse（カタログ番号C001329）はサイアジェンから購入しました。」と引用してください。
Immunodeficient Mice
Humanized Immune System Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Immunodeficient Mice
Humanized Immune System Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
gc, p64, [g]c, CD132, gamma(c)
NCBI ID
染色体
Chr X
MGI ID
さらに
系統詳細
NKG mice (Product number: C001316) are a kind of severe immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX) to obtain the humanized mice with the human immune system.
PBMC humanized mice refer to the immune system humanized mouse model constructed by transplanting human peripheral blood mononuclear cells (PBMC) into immunodeficient mice (such as NKG). NKG mice transplanted with PBMC (huPBMC-NKG) have high efficiency and fast immune reconstitution. The average proportion of human CD45+ in peripheral blood (PB) is about 50% after 3 weeks of transplantation, and the reconstituted immune cells are mainly lymphoid T cells. Human T cells generated after PBMC injection will attack mouse recipient cells, resulting in graft-versus-host disease (GvHD), so this model can be used to evaluate GvHD drugs.
系統作製戦略
Female NKG mice aged 6 weeks were selected to inject PBMC for the construction of the huPBMC-NKG model, and the construction period was 2-3 weeks.
適用分野
Short-term studies requiring mature T cells in the fields of tumor immunity, Hematopoiesis, and gene therapy for hematologic and infectious diseases.
検証 Data
1. Survival curve
Around 35 days post engraftment, huPBMC-NKG mice gradually began to die as Graft-versus-Host Disease (GvHD) appeared. After 60 days of transplantation, about 20% of the mice were still alive.
Figure 1. The survival curve of huPBMC-NKG mice.
2. The reconstruction status of the immune system.
（1）Detection of Human CD45+ Cells in Peripheral Blood (PB)
After transplantation of human PBMCs, the content of human leukocytes in the peripheral blood gradually increased. After 3 weeks, the average proportion of human CD45+ cells exceeded 40% and the reconstruction speed was relatively fast. After transplantation, the humanization ratio remained at a high level for 3-6 weeks.
Figure 2. The proportion of human CD45+ cells in peripheral blood (PB) of huPBMC-NKG mice.
（2）Detection of Human CD3+ Cells in Peripheral Blood (PB)
About 95%- 100% of hCD45+ cells in huPBMC-NKG mice belong to hCD3+ T cells 3 weeks after human PBMC transplantation, indicating that the reconstruction of the human immune system in huPBMC-NKG mice was dominated by T cells.
Figure 3. The proportion of human CD3+ T cells in the peripheral blood of huPBMC-NKG mice.
（3）The Graft-versus-Host Disease (GvHD)
GvHD symptoms begin to appear around 28d. Mice lost a significant amount of body weight and the body weight was reduced by more than 20% after 45d.
Figure 4. GvHD scores and body weight changes in NKG mice after PBMC transplantation.
関連リソース
お問い合わせ
ご不明な点やご質問などございましたら、お気軽にお問い合わせください。担当スタッフがサポートさせていただきます。下記のフォームにご記入いただければ、1〜2営業日以内に折り返しご連絡いたします。
Related Product
All Related ProductsResources
Publications
Nature
2025-09-10
Amplifying antigen-induced cellular responses with proximity labelling
続きを読む
Cell Reports Medicine
2025-03-17
An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B a1/2 shedding
続きを読む
Cell Reports Medicine
2025-02-24
An epitope-directed mRNA vaccine inhibits tumor metastasis through the blockade of MICA/B α1/2 shedding
続きを読む
Cell Reports Medicine
2025-08-26
Identification and validation of intratumoral microbiome associated with sensitization to immune checkpoint inhibitors
続きを読む
International Immunopharmacology
2024-03-09
Biomimetic exosomal vesicles loaded with siRNA improves antitumor immune responses by inhibiting the secretion of tumor-derived exosome PD-L1
続きを読む
Cancer & Metabolism
2026-04-01
PER2 knockdown drives immunotherapy resistance in gastric cancer via metabolic reprogramming of myeloid-derived suppressor cells
続きを読む
Communications Biology
2025-04-01
Hantaan virus infection induces human mucosal-associated invariant T cell pyroptosis through IRE1α pathway
続きを読む
International Immunopharmacology
2024-03-10
Biomimetic exosomal vesicles loaded with siRNA improves antitumor immune responses by inhibiting the secretion of tumor-derived exosome PD-L1
続きを読む
Nature
2025-09-01
Amplifying antigen-induced cellular responses with proximity labelling
続きを読む
Items: 1 to 5 of 9
1
2
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。